10693 results for 'case 3'

PD-L1 in Cancer Immunotherapy: Insights from Recent ResearchRecent advancements in cancer immunotherapy have underscored the critical role of programmed death-ligand 1 (PD-L1) in mediating immune evas

Immunotherapy has become a central pillar in the fight against cancer, with a focus on enhancing the body’s natural defenses. Among the molecules at the forefront of immunotherapeutic res

Quick Info Section: Key Facts About CevostamabWhat is Cevostamab?Cevostamab is an investigational monoclonal antibody targeting CD47, a cell surface protein that helps cancer cells evade

Quick Facts About GlenzocimabWhat is Glenzocimab?Glenzocimab is an innovative monoclonal antibody designed to reduce the risk of ischemic stroke by selectively targeting platelet glycopr

Spatial Transcriptomics: Mapping the Future of Medicine at Cellular Resolution Imagine being able to create a detailed map of a city, not just showing the streets and buildings, but also revealing th

주요 포인트: COVID-19,SARS-COV-2에의한 유행성 코로나 바이러스 질환은 예비 데이터에 따르면, 전형적인 혈청 전환 및 면역 글로불린 클래스 (이소형) 전환 시간 과정을 따르는 것으로 나타났다. 증상 발병 2 주 후 임상 중증도와 항

Quick Facts About PraluzatamabWhat is Praluzatamab?Praluzatamab is an experimental monoclonal antibody that targets CD47, a “don’t eat me” signal used by cancer cells to evade immune des

Exploring sepsis: a critical imbalance in the immune response to infection. Key Takeaways: Sepsis is a severe, immune-driven response to infection causing systemic inflammation and potent

Unravel the complexities of bone resorption, a crucial biological process essential for skeletal health and calcium regulation, through the intricate roles of osteoclasts and osteoblasts. Ke

Enzymology · Protein DegradationProtease vs Peptidase: Understanding the DifferenceProteases and peptidases are the enzymes that cleave peptide bonds — breaking proteins down into peptides and peptide

Introduction to CD122 in Immunotherapy CD122, also known as the interleukin-2 receptor beta chain (IL-2Rβ), is a critical component of the immune system's response to pathogens and malign

What You Need to Know About PolatuzumabWhat is Polatuzumab??Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, a component of the B-cell receptor, used primarily in B-cel

For decades, immunologists believed that only adaptive immunity—the sophisticated system of T cells and B cells—could form lasting memories of past infections. The innate immune system, our body's fir

Custom Assay Entwicklung: Wann sich der Aufwand wirklich lohnt Ein kundenspezifischer Assay ist dann angezeigt, wenn Standardmethoden die In-vivo-Relevanz, Matrixeffekte oder die Messbarkeit neuartig

Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha

Quick Facts About SecukinumabWhat is SecukinumabSecukinumab is a monoclonal antibody that targets interleukin-17A (IL-17A), a key cytokine involved in inflammatory and autoimmune respons

Quick Facts About FarletuzumabWhat is Farletuzumab?Farletuzumab is a humanized monoclonal antibody targeting folate receptor alpha (FRα), a protein overexpressed in ovarian and other epi

CD155 is read by four different receptors, and only one of them turns the killing programme on. The nectin and nectin-like ligands induced on stressed and transformed cells are simultaneously an acti

By Sophie Arthur How many diseases and conditions do you think exist in this world? Thousands? Hundreds of thousands? Maybe even millions? Unfortunately, I don’t know the answer. But what I